QLGN - Pangali EV/EBITDA Qualigen Therapeutics, Inc.

This chart illustrates that the market value of Qualigen Therapeutics (QLGN) on the GURU.Markets platform is , highlighting a lack of sales for the biotech startup, which relies on issuing new shares to fund its trials. The business focuses on developing nanoparticles to combat oncology and viruses. Supply chain resilience is maintained through the distribution of production capacities, which mitigates risks during medication delivery.

The expansion of the antiviral and oncology pipeline of Qualigen Therapeutics (QLGN) requires significant capital expenditures, making the analysis of debt load critical. The EV/EBITDA value, accounting for total debt, compares the total enterprise value with operating profit before interest, taxes, depreciation, and amortization, stripping the valuation of the influence of the financing structure. A decline in this curve signals that assets are undervalued, while a sharp increase warns that the stock is overbought.